CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on “antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria.”

CARB-X has a mission to “Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $455 million in BARDA funds with matching funds from Wellcome Trust.”

The full press release is reprinted below:

CARB-X announced today its 2018 rounds of funding to support research into the development of antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria.

• 2018 Funding Round 1will open for Expressions of Interest on March 22 through March 29, 2018, with the scope restricted to new classes of direct-acting small molecule and large molecule antibacterials that target certain Gram-negative bacteria.
• 2018 Funding Round 2will follow, with Expressions of Interest welcome starting on June 1 through June 8, 2018. Round 2 funding includes direct-acting therapeutics and covers a broader scope of therapeutics, vaccines, diagnostics and devices that meet certain criteria.

The scope for each 2018 round is highly specific. In addition, applicants for both rounds must be going concerns (financially solvent companies or research teams with funding in place for operations for at least 12 months) and also own or have rights to the intellectual property required to carry out the project.

CARB-X welcomes applications from around the world.

Full details of the scope of both funding rounds can be found here.

Information about the application process can be found here.